Информация в данном разделе предназначена только для работников здравоохранения.
Являетесь ли Вы медицинским специалистом?

ДА НЕТ

Список литературы:

  1. Vilsbøll T., Holst J. J. Incretins, insulin secretion and type 2 diabetes mellitus //Diabetologia. – 2004. – Vol. 47. – №. 3. – P. 357-366.
  2. Buteau J. GLP-1 receptor signaling: effects on pancreatic β-cell proliferation and survival //Diabetes & metabolism. – 2008. – Vol. 34. – P. S73-S77.
  3. Инструкция к препарату Оземпик®.
  4. Yabe D. et al. Glucagon-like peptide-1 receptor agonist therapeutics for total diabetes management: assessment of composite end-points. – 2015.
  5. ClinicalTrials.gov. SUSTAIN 6 [NN9535-3744]. Available at: https://clinicaltrials.gov/show/NCT01720446. Last accessed May 2020
  6. Kapitza C. et al. Semaglutide, a once‐weekly human GLP‐1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel //The Journal of Clinical Pharmacology. – 2015. – Vol. 55. – №. 5. – P. 497-504.
  7. Hausner H. et al. Effect of once-weekly subcutaneous treatment with semaglutide, a GLP-1 analog, on metformin, warfarin, atorvastatin and digoxin in healthy subjects //ENDO. – 2016.
  8. Marsico F. et al. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials //European Heart Journal. – 2020.
  9. Mannucci E. et al. Glucagon‐like peptide‐1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta‐analysis and subgroup analysis of randomized controlled trials //Diabetes, Obesity and Metabolism. – 2020. – Vol. 22. – №. 2. – P. 203-211.
  10. ClinicalTrials.gov. SUSTAIN 1 [NN9535-3623]. Available at: https://clinicaltrials.gov/show/NCT02054897. Last accessed May 2020
  11. ClinicalTrials.gov. SUSTAIN 2 [NN9535-3626]. Available at: https://clinicaltrials.gov/show/NCT01930188. Last accessed May 2020
  12. ClinicalTrials.gov. SUSTAIN 3 [NN9535-3624]. Available at: https://clinicaltrials.gov/show/NCT01885208. Last accessed May 2020
  13. ClinicalTrials.gov. SUSTAIN 4 [NN9535-3625]. Available at: https://clinicaltrials.gov/show/NCT02128932. Last accessed May 2020
  14. ClinicalTrials.gov. SUSTAIN 5 [NN9535-3627]. Available at: https://clinicaltrials.gov/show/NCT02305381. Last accessed May 2020
  15. Arnett D. K. et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines //Journal of the American College of Cardiology. – 2019. – Vol. 74. – №. 10. – e177-e232.
  16. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. – 9-й выпуск, 2019.
  17. Paes A. H. P., Bakker A., Soe-Agnie C. J. Impact of dosage frequency on patient compliance //Diabetes care. – 1997. – Vol. 20. – №. 10. – P. 1512-1517.